LGR5 and colorectal cancer: No active CAR clinical trials directed against this target were identified on clinicatrials.gov (accessed on 9 January 2023), although Carina Biotech Pty Ltd. have received a safe to proceed notification for an Investigational New Drug application to the US FDA for Phase 1/2a testing of LGR5 CAR T-cells in patients with colorectal cancer (https://www.yahoo.com/now/carina-biotech-receives-fda-safe-235500803.html, accessed on 24 January 2023).